Tech Transfer eNews Blog

Purdue start-up develops injectable drug to heal bones in aging patients


By Jesse Schwartz
Published: February 19th, 2020

A Purdue University start-up is developing an injectable drug that is designed to heal broken bones faster and strengthen weak bones in aging patients.

Novosteo is moving closer to launching clinical trials for its drug, NOV004, which was developed in the lab of co-founder Philip S. Low in the Purdue Institute of Drug Discovery. The start-up is already looking at future applications for the drug, such as dental implants, head fractures and knee replacements.

Biotech entrepreneur Scott Salka recently joined Novosteo as executive chair to help the start-up move its bone-healing drug into clinical trials and ultimately into the hands of doctors and patients.

“We have been working on some amazing science with people truly dedicated to making a difference in reducing the mortality and improving the quality of life for our aging population,” says Salka. “We have completed preclinical studies with NOV004 and are looking to take it to clinical trials later this year.”

Novosteo licensed the drug through the Purdue Research Foundation Office of Technology Commercialization, and it has received support from the Purdue Foundry start-up hub.

Source: Technology Networks

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment